Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. Fujian Cosunter Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Fuzh… Read more
Fujian Cosunter Pharmaceutical Co Ltd (300436) - Total Assets
Latest total assets as of September 2025: CN¥1.52 Billion CNY
Based on the latest financial reports, Fujian Cosunter Pharmaceutical Co Ltd (300436) holds total assets worth CN¥1.52 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Fujian Cosunter Pharmaceutical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Fujian Cosunter Pharmaceutical Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Fujian Cosunter Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Fujian Cosunter Pharmaceutical Co Ltd's total assets of CN¥1.52 Billion consist of 28.3% current assets and 71.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.0% |
| Accounts Receivable | CN¥74.72 Million | 5.2% |
| Inventory | CN¥114.48 Million | 8.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥257.49 Million | 17.9% |
| Goodwill | CN¥58.97 Million | 4.1% |
Asset Composition Trend (2011–2024)
This chart illustrates how Fujian Cosunter Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Fujian Cosunter Pharmaceutical Co Ltd's current assets represent 28.3% of total assets in 2024, a decrease from 47.1% in 2011.
- Cash Position: Cash and equivalents constituted 10.0% of total assets in 2024, down from 35.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, an increase from 9.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 17.9% of total assets.
Fujian Cosunter Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Fujian Cosunter Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Fujian Cosunter Pharmaceutical Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Fujian Cosunter Pharmaceutical Co Ltd generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Fujian Cosunter Pharmaceutical Co Ltd is currently not profitable relative to its asset base.
Fujian Cosunter Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.03 | 0.79 | 0.88 |
| Quick Ratio | 0.77 | 0.52 | 0.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥18.50 Million | CN¥ -115.44 Million | CN¥ -36.58 Million |
Fujian Cosunter Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Fujian Cosunter Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 44.33 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | -10.9% |
| Total Assets | CN¥1.44 Billion |
| Market Capitalization | $1.43 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Fujian Cosunter Pharmaceutical Co Ltd's assets close to their book value ( 1.00x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Fujian Cosunter Pharmaceutical Co Ltd's assets decreased by 10.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Fujian Cosunter Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Fujian Cosunter Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.44 Billion | -10.88% |
| 2023-12-31 | CN¥1.61 Billion | +8.00% |
| 2022-12-31 | CN¥1.49 Billion | +3.32% |
| 2021-12-31 | CN¥1.45 Billion | +43.85% |
| 2020-12-31 | CN¥1.01 Billion | +12.27% |
| 2019-12-31 | CN¥895.88 Million | +4.84% |
| 2018-12-31 | CN¥854.52 Million | +16.03% |
| 2017-12-31 | CN¥736.47 Million | +5.11% |
| 2016-12-31 | CN¥700.67 Million | +16.64% |
| 2015-12-31 | CN¥600.70 Million | +168.03% |
| 2014-12-31 | CN¥224.11 Million | +13.46% |
| 2013-12-31 | CN¥197.53 Million | +32.21% |
| 2012-12-31 | CN¥149.41 Million | +36.71% |
| 2011-12-31 | CN¥109.29 Million | -- |